552 related articles for article (PubMed ID: 27528380)
21. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
24. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
25. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of metabolic response with
Segreto S; Fonti R; Ottaviano M; Pellegrino S; Pace L; Damiano V; Palmieri G; Del Vecchio S
Cancer Imaging; 2017 Mar; 17(1):10. PubMed ID: 28264726
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses.
D'Angelo EC; Paolisso P; Vitale G; Foà A; Bergamaschi L; Magnani I; Saturi G; Rinaldi A; Toniolo S; Renzulli M; Attinà D; Lovato L; Lima GM; Bonfiglioli R; Fanti S; Leone O; Saponara M; Pantaleo MA; Rucci P; Di Marco L; Pacini D; Pizzi C; Galiè N
JACC Cardiovasc Imaging; 2020 Nov; 13(11):2400-2411. PubMed ID: 32563654
[TBL] [Abstract][Full Text] [Related]
28. Improving the imaging diagnostic strategy for pulmonary artery masses based on
Hong C; Hou P; Chen HM; Zhong KX; Guo WL; Lin JL; Wu XF; Lei YX; Jia Q; Liu CL; Li SY; Wang XL
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4109-4121. PubMed ID: 35732973
[TBL] [Abstract][Full Text] [Related]
29. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
Takehana CS; Twist CJ; Mosci C; Quon A; Mittra E; Iagaru A
Nucl Med Commun; 2014 Mar; 35(3):276-81. PubMed ID: 24296883
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary mucosa-associated lymphoid tissue lymphoma:
Albano D; Borghesi A; Bosio G; Bertoli M; Maroldi R; Giubbini R; Bertagna F
Br J Radiol; 2017 Nov; 90(1079):20170311. PubMed ID: 28830222
[TBL] [Abstract][Full Text] [Related]
31. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
32. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
34. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
35. Utility of baseline, interim and end-of-treatment
Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
[TBL] [Abstract][Full Text] [Related]
36. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT.
Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX
Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic and Clinical Impact of Staging
Albano D; Ferro P; Bosio G; Fallanca F; Re A; Tucci A; Maria Ferreri AJ; Angelillo P; Gianolli L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e457-e464. PubMed ID: 31129112
[TBL] [Abstract][Full Text] [Related]
38. The role of ¹⁸F-FDG uptake features in the differential diagnosis of solitary pulmonary lesions with PET/CT.
Zhao M; Chang B; Wei Z; Yu H; Tian R; Yuan L; Jin H
World J Surg Oncol; 2015 Sep; 13():271. PubMed ID: 26369407
[TBL] [Abstract][Full Text] [Related]
39. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer.
Liao S; Lan X; Cao G; Yuan H; Zhang Y
Clin Nucl Med; 2013 Sep; 38(9):715-20. PubMed ID: 23856825
[TBL] [Abstract][Full Text] [Related]
40. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
